Board of Directors2019-09-08T21:57:24+00:00

Board of Directors

Steve Engle – Non-Executive Chairman

Steve Engle on the Prescient Therapeutics Board of Directors

Steven Engle is the CEO of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Previously, Mr. Engle served as CEO of Averigon, an advisory firm to the life science industry, as Chairman and CEO of XOMA, a developer of antibody therapeutics for metabolic, inflammatory, oncology and other diseases, and which had partnerships with multiple pharmaceutical companies, and as Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Steven Engle was VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. Mr. Engle is a director on the board of AROA, a developer and marketer of regenerative products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with a focus in biomedical engineering.

Steven Yatomi-Clarke – CEO and Managing Director

Steven Yatomi-Clarke Prescient Therapeutics Board of Directors

Steven Yatomi-Clarke has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies.  Mr Yatomi-Clarke previously held a position as a Director in Corporate Finance at Patersons Securities.

Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.

He has a strong track record of financing multiple private and public biotechnology companies, bringing more than 15 years’ experience in investment banking with a particular focus on the life sciences/biotechnology sector.

Mr Yatomi-Clarke has consistently been one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments for medical device and pharmaceutical companies.

Paul Hopper – Executive Director

Paul Hopper is on Prescient Therapeutics Board of Directors

Mr Hopper has international & ASX biotech capital markets experience, particularly in oncology. He is the former Chairman of Viralytics (acquired in June 2018 by Merck for $500m), Founder & Director of Prescient, Founder of Imugene & Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science.

Dr James Campbell – Non-Executive Director

Dr James Campbell Prescient Therapeutics Board of Directors

Dr Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. Dr Campbell sits on the Advisory Board of Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT).